ImClone names chief scientific, medical officers
Executive Summary
Former Wyeth VP-Oncology Philip Frost joins ImClone as chief scientific officer, filling a position that has been open since Harlan Waksal left in July 2003. ImClone also named Eric Rowinsky chief medical officer. Rowinsky, previously director of the Cancer Therapy & Research Center's Institute for Drug Development in San Antonio, will have responsibility for the colorectal cancer drug Erbitux (cetuximab)...
Former Wyeth VP-Oncology Philip Frost joins ImClone as chief scientific officer, filling a position that has been open since Harlan Waksal left in July 2003. ImClone also named Eric Rowinsky chief medical officer. Rowinsky, previously director of the Cancer Therapy & Research Center's Institute for Drug Development in San Antonio, will have responsibility for the colorectal cancer drug Erbitux (cetuximab).... |